For most families, private cord blood banking through ViaCord or any similar company is unlikely to pay off. The chance that your child will ever need their own stored cord blood is roughly 1 in 2,500, and leading medical organizations recommend public donation over private storage for families without a specific medical reason to bank. That does not mean the service is a scam, but the value proposition rests on a very unlikely scenario, and understanding exactly how unlikely helps you make an informed decision.
What You Actually Pay
ViaCord’s pricing, like most private cord blood banks, breaks into two pieces: an upfront collection and processing fee, and an annual storage fee that continues for as long as you keep the sample banked. As of recent years, the initial fee for cord blood alone typically runs in the range of $1,000 to $2,000, with annual storage fees around $150 to $175. Cord tissue banking (which stores a different type of stem cell from the umbilical cord itself) is often sold as an add-on, pushing the initial cost higher. Over 20 years of storage, which is the timeframe many families envision, total costs can easily reach $4,000 to $5,000 or more.
A cost-effectiveness study modeled private cord blood banking at roughly $3,620 for 20 years of collection and storage, and found it came out to over $1.3 million per life-year gained, which is far above what health economists consider a reasonable expenditure.1PubMed. Cost-effectiveness of private umbilical cord blood banking To put that in perspective, the study found that private banking would only become cost-effective if the total price dropped below about $262, or if the chance of needing a transplant were better than about 1 in 110. Neither condition is close to reality for most families.
How Often Privately Banked Cord Blood Gets Used
This is the central question, and the numbers are sobering. Decision-analytic modeling has estimated that the probability of a child needing their own (autologous) stem cell transplant is about 0.04%, with a 0.07% chance that a sibling would need an allogeneic transplant from the banked unit.2Obstetrical & Gynecological Survey. Cost-Effectiveness of Private Umbilical Cord Blood Banking Those probabilities combine to less than 1 in 1,000 over the child’s lifetime. The American Academy of Pediatrics has noted that there is little evidence supporting the use of privately stored cord blood for self-use.3Pediatrics. Cord Blood Banking for Potential Future Transplantation
Part of the reason the self-use case is weak comes down to biology. If a child develops leukemia, for instance, the genetic mutations that led to the cancer may already be present in the cord blood collected at birth. Transplanting those same cells back into the child could reintroduce the disease. This is why most transplants for blood cancers use donor cells rather than the patient’s own, which undercuts one of the primary selling points of private banking.
When Private Banking Genuinely Makes Sense
The picture changes if your family has a child already diagnosed with a condition treatable by stem cell transplant. Cord blood transplants from HLA-identical siblings have shown strong outcomes: the Eurocord registry has reported four-year overall survival of about 91% for children with non-malignant diseases and 56% for those with malignancies, across over 500 sibling transplants.4PubMed Central. Family-directed umbilical cord blood banking. For families where an older sibling has leukemia, sickle cell disease, thalassemia, or certain immune or metabolic disorders, directed banking of a new baby’s cord blood is a medically supported decision.
The AAP’s policy reflects this distinction clearly: public cord blood banking is the preferred method for most families, but there is a recognized role for private banking when a family member has a known fatal illness that could be treated with a healthy cord blood transplant.3Pediatrics. Cord Blood Banking for Potential Future Transplantation If your obstetrician or pediatric hematologist has specifically discussed sibling-directed banking with you, that is a meaningfully different conversation from the one in the marketing brochure sent to all expecting parents.
The Public Banking Alternative
Public cord blood banks collect donations at no cost to the family, process them to clinical standards, and list them on registries available to any patient who needs a transplant. If your child or a family member later needs cord blood, they can search the public registry just like anyone else. The trade-off is that you give up ownership of the specific unit, so there is no guarantee it will still be available if you need it years later.
The matching situation in public banks has improved substantially. A large study of the U.S. registry found that while perfectly matched cord blood units are rare for any individual patient, units mismatched at one or two HLA markers are available for nearly all patients under 20 and for more than 80% of older patients across all racial and ethnic groups.5PubMed Central. HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. Registry Cord blood transplants tolerate more HLA mismatch than bone marrow transplants, which is one of their advantages. Research on public inventories has also shown that as banks grow, the gap in match likelihood between different ethnic groups progressively shrinks.6PubMed. Reducing ethnic disparity in access to high-quality HLA-matched cord blood units for transplantation: analysis of the Canadian Blood Services’ Cord Blood Bank inventory
Not every hospital participates in a public cord blood collection program, which is one practical limitation. If public donation matters to you, it is worth checking early in your pregnancy whether your delivery hospital is a collection site.
Cord Blood Versus Other Stem Cell Sources
Private banks sometimes imply that cord blood is the only viable source of transplantable stem cells, but patients who need a transplant have several options. Bone marrow and peripheral blood stem cells from adult donors are the most common sources. A head-to-head comparison published in the New England Journal of Medicine found that outcomes after mismatched cord blood transplants were similar to mismatched bone marrow transplants for adults with leukemia, with comparable rates of treatment-related death and overall survival, though hematopoietic recovery was slower with cord blood.7PubMed. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia Cord blood does offer certain biological advantages: it appears to have higher long-term repopulating capacity and shows reduced relapse rates in some comparisons.8PubMed Central. Is There Any Reason to Prefer Cord Blood Instead of Adult Donors for Hematopoietic Stem Cell Transplants?9PubMed Central. Concise review: umbilical cord blood transplantation: past, present, and future
Newer approaches have also expanded the options. Haploidentical transplantation, which uses a partially matched family donor (often a parent), has become increasingly common and can be combined with a cord blood unit for better engraftment. This means even families who did not bank cord blood privately often have viable transplant options available through registries or family donors.
What About Cord Tissue Banking
ViaCord and competitors increasingly market cord tissue banking alongside cord blood. Cord tissue contains mesenchymal stem cells (MSCs), which are a different cell type than the blood-forming stem cells in cord blood. These MSCs can differentiate into bone, cartilage, and fat cells, and they have properties that could be useful for tissue repair and immune modulation.10PubMed Central. Umbilical cord-derived mesenchymal stem cells: Their advantages and potential clinical utility Research has suggested that cord-derived MSCs may eventually prove useful for autoimmune and neurodegenerative conditions.11PubMed. Umbilical cord mesenchymal stem cells: the new gold standard for mesenchymal stem cell-based therapies?
The catch is that cord tissue MSCs are not yet used in standard clinical practice. They remain investigational. No FDA-approved therapy currently requires stored cord tissue. When private banks advertise cord tissue storage, they are selling you a bet that the research will eventually produce approved treatments and that your child’s stored sample will be compatible with those treatments. That could happen, but it is speculative, and you are paying real money now for a potential benefit that may never materialize.
Experimental Therapies and the Future Argument
Much of the private banking pitch leans on the idea that stem cell therapies are expanding, so banking now hedges against future medical needs your child might have. There is some truth to the direction of the science, but the specifics matter. Early-phase trials have explored cord blood infusions for conditions like cerebral palsy and autism spectrum disorder, and results have been cautiously encouraging. A study of sibling cord blood infusions in young children with cerebral palsy found improvements in gross motor function six months after infusion.12PubMed Central. Sibling umbilical cord blood infusion is safe in young children with cerebral palsy A small Phase I trial of autologous cord blood infusion in children with autism found the treatment was safe and showed behavioral improvements over 12 months, with greater gains in children who had higher baseline cognitive abilities.13Stem Cells Translational Medicine. Autologous Cord Blood Infusions Are Safe and Feasible in Young Children with Autism Spectrum Disorder: Results of a Single-Center Phase I Open-Label Trial
These are real findings, but they are preliminary. Phase I trials are designed to test safety and feasibility, not to prove effectiveness. Neither cerebral palsy nor autism has an FDA-approved cord blood therapy. The gap between “safe and shows signals of benefit in a small trial” and “proven treatment available at your hospital” is years of additional research, larger trials, and regulatory review. Private banks sometimes blur that distinction in their marketing.
Does Cord Blood Actually Last That Long in Storage
One concern parents have is whether a sample stored at birth would still work decades later. The evidence here is actually reassuring. A study from the José Carreras Cord Blood Bank tested units that had been cryopreserved for up to 29 years and found no significant loss of quality. The time spent frozen had no detrimental effect on engraftment after transplantation.14Stem Cells Translational Medicine. Long-Term Stability of Cord Blood Units After 29 Years of Cryopreservation: Follow-Up Data From the José Carreras Cord Blood Bank Earlier work confirmed that cryopreservation for at least 10 years had no impact on cell recovery, viability, or clinical outcomes in transplantation.15PubMed Central. Impact of long-term cryopreservation on single umbilical cord blood transplantation outcomes Even at the 15-year mark, stem and progenitor cells retained their ability to proliferate, self-renew, and engraft in animal models at levels comparable to fresh cord blood.16PubMed Central. High-efficiency recovery of functional hematopoietic progenitor and stem cells from human cord blood cryopreserved for 15 years
So if you do bank, you can be confident the cells will remain viable for at least as long as any current study has tested. Storage durability is not the weak link in the private banking value proposition.
Collection Is Not Always Straightforward
Something the brochures gloss over is that not every cord blood collection produces a usable sample. A study of over 10,000 cryopreserved samples found that about 8% tested positive for bacterial contamination.17PubMed Central. Contamination Rate of Cryopreserved Umbilical Cord Blood Is Inversely Correlated with Volume of Sample Collected and Is also Dependent on Delivery Mode Samples with lower volumes (under 60 mL) had contamination rates around 12%, and vaginal deliveries were associated with much higher contamination than cesarean deliveries (roughly 10% versus 1.4%). Another study of over 13,000 units found an overall contamination rate of 4%, though the rate improved dramatically over time, falling from 10% to about 1% as collection techniques matured.18PubMed. Factors affecting microbial contamination rate of cord blood collected for transplantation
Beyond contamination, the volume and total cell count of a collection can vary widely. Some collections simply do not yield enough cells to be useful for transplantation, particularly for larger children or adults. Private banks will store whatever is collected, but a unit with too few cells may never be clinically useful. This is worth asking about: what is the bank’s policy if the sample does not meet minimum thresholds? Some banks will store it regardless and continue charging you annual fees.
Delayed Cord Clamping and the Timing Trade-Off
Current obstetric guidelines recommend delaying cord clamping for at least 30 to 60 seconds after birth, because allowing more blood to flow from the placenta to the newborn improves the baby’s hemoglobin levels and iron stores. A randomized trial found that a five-minute delay in clamping led to significantly higher hemoglobin levels in the infant (about 19.4 versus 17.8 g/dL) compared to immediate clamping, with no increase in jaundice risk.19Journal of Perinatology. Effects of delayed cord clamping on residual placental blood volume, hemoglobin and bilirubin levels in term infants: a randomized controlled trial
The tension is straightforward: blood that flows into the baby is blood that does not end up in the collection bag. Delayed clamping reduces the volume of cord blood available for banking, and lower volumes are associated with higher contamination rates and fewer total cells. Some families and providers try to split the difference with a brief delay followed by collection, but there is an inherent trade-off. If you are planning to bank, discuss this with your delivery team beforehand so everyone is on the same page about priorities. Most pediatricians and midwives will prioritize the baby’s immediate benefit from delayed clamping over cord blood collection.
How ViaCord Compares to Other Private Banks
ViaCord is one of the larger private cord blood banks in the United States, and its pricing, accreditation, and services are broadly similar to competitors like Cord Blood Registry (CBR, now part of CooperSurgical) and Cryo-Cell. All major private banks are accredited by AABB (formerly the American Association of Blood Banks), which sets standards for collection, processing, and storage. The differences between them tend to be in pricing structure, bundling options for cord blood plus cord tissue, customer service reputation, and fine print around what happens if the company is sold or goes out of business.
That last point is not trivial. The private cord blood banking industry has seen consolidation and financial instability over the years. If a company folds or is acquired, your stored sample could be transferred to another facility, and terms of service might change. Before signing up, it is worth reading the contract carefully: who owns the sample, what happens if the bank ceases operations, and whether annual fees can increase.
What Families With Mixed Ethnic Backgrounds Should Know
Families from underrepresented ethnic groups sometimes hear that private banking is more important for them because finding a matched donor from a public registry is harder. There is a grain of truth here: HLA diversity is greater in non-European populations, and historically, minority patients have had lower match rates on registries. However, cord blood’s tolerance for partial HLA mismatch reduces this gap considerably. As public inventories grow, match likelihoods are improving across all ethnic groups.6PubMed. Reducing ethnic disparity in access to high-quality HLA-matched cord blood units for transplantation: analysis of the Canadian Blood Services’ Cord Blood Bank inventory Private banking could provide an additional safety net for these families, but it is still a hedge against a very low-probability event, and donating to a public bank may do more collective good by increasing diversity in the public registry.
Reading the Marketing With a Critical Eye
Private cord blood banks are businesses, and their marketing reflects that. A few patterns are worth watching for. First, testimonials from families whose children were saved by stored cord blood are real, but they represent the tiny fraction of families who actually used their sample. You rarely see testimonials from the 99.9% of families who paid for 20 years of storage and never needed it. Second, lists of “80+ diseases treatable with cord blood” often include conditions where autologous (self) transplant would not be the treatment of choice, or where the standard of care uses donor cells from a registry rather than the patient’s own. Third, language about “future therapies” and “regenerative medicine potential” describes genuine areas of research but frames speculative science as if clinical applications are imminent. The gap between laboratory promise and bedside therapy remains wide for most of these conditions.
None of this means the companies are dishonest, exactly. But the emotional weight of the decision, made while expecting a baby, can make it hard to evaluate the actual probabilities. The evidence consistently suggests that for families without a known medical indication, the money spent on private cord blood banking could be better allocated elsewhere, whether that is an education fund, life insurance, or simply staying in your savings account.